Luo S, Wang T, Qin H, Lei H, Xia Y. Obligatory role of heat shock protein 90 in iNOS induction.
nuclear factor-B; inducible nitric oxide synthase; geldanamycin; Janus kinase-signal transducers and activators of transcription 1 NITRIC OXIDE (NO) is not only a signaling molecule, it also plays crucial roles in cell injury and host defense (14, 16) . Depending on its concentrations, NO can convey cell signaling or cause cell damage. In mammals, NO is synthesized by a family of NO synthase (NOS) consisting of three isoforms. NO generated from the neuronal and endothelial NOS (nNOS and eNOS, respectively) primarily participates in neuronal signal transmission and cardiovascular regulation (18) . The inducible NOS (iNOS), however, plays important roles in inflammation and immune defense. Compared with the other two isoforms, iNOS is a high-output enzyme with the strongest NO-generating potency (6) . The immune system employs the massive NO production by iNOS to kill bacteria, viruses, and tumor cells (14, 16, 18) . Indeed, iNOS null mice have been found to be more vulnerable to the death of bacterial infection (15) . On the other hand, iNOS induction also contributes to the process of cell injury in various diseases including myocardial infarction and heart failure (11) . Cardiac iNOS overexpression results in severe cardiac injury and sudden death in transgenic mice (17) .
Unlike the constitutively existing nNOS and eNOS, little iNOS is present in quiescent cells. The expression of iNOS is induced by inflammatory mediators such as bacterial endotoxins and cytokines (16, 18) . Lipopolysaccharide (LPS) and interferon-␥ (IFN-␥) are the two extensively characterized iNOS inducers (10) . LPS stimulates iNOS gene transcription through the canonical IB kinase/nuclear factor-B (IKK-NF-B) pathway. LPS binds with the Toll-like receptors leading to IKK phosphorylation and activation. Active IKK subsequently phosphorylates IB, and this promotes its degradation via the ubiquitin-proteasome system (8) . The removal of the inhibitory IB liberates transcriptional factor NF-B, which subsequently enters nuclei and initiates iNOS mRNA transcription. On the other hand, IFN-␥ triggers iNOS gene transcription through the Janus kinase (JAK)-signal transducers and activators of transcription 1 (STAT1) cascade (16, 10) . Upon the binding with IFN-␥, its receptors undergo dimerization or oligomerization leading to the JAK transphosphorylation and activation. JAK phosphorylates and activates transcriptional factor STAT1, which then translocates into nuclei and triggers iNOS gene transcription (12, 19) . IKK-NF-B and JAK-STAT1 are the two principal pathways that drive iNOS induction by extracellular stimuli. In addition to LPS and IFN-␥, many other cytokines including tumor necrosis factor (TNF)-␣ and interleukin (IL)-1 also induce iNOS expression through either NF-B or STAT1 (16, 19, 2) .
Another distinctive feature of iNOS is its constant activity once expressed. The catalytic function of all NOS isoforms requires the binding with the cofactor calmodulin (CaM). The binding of CaM to nNOS or eNOS is initiated by the increased cytosolic Ca 2ϩ concentrations. In contrast, iNOS binds with CaM at resting cellular Ca 2ϩ levels, and this affords iNOS full activity in quiescent cells (6, 18) . Thus the magnitude of NO formation from iNOS is believed to be largely determined by the levels of iNOS expression. However, recent studies demonstrated that iNOS function can be profoundly influenced by protein-protein interactions. We found that iNOS associates with heat shock protein 90 (Hsp90), and this association augments iNOS activity (27) . Hsp90 is an intracellular molecular chaperone known to be vital for the maintenance of protein conformation and function (13) . Hsp90 has broad roles in signal transduction as well as many other processes in cells (20) . Although the prior studies identified Hsp90 as an allosteric enhancer of iNOS, it remains unclear whether Hsp90 affects iNOS expression. The present study aims to define the role of Hsp90 in iNOS induction. Our studies, performed on both cultured cells and infarcted myocardium in vivo, demonstrate that Hsp90 is essential for iNOS gene transcription.
MATERIALS AND METHODS

Materials.
Cell culture materials were purchased from Invitrogen (Carlsbad, CA). The antibody against iNOS was from BD Transduction Laboratories. Antibodies against IKK, IB, STAT1, phospho-IKK, phospho-NF-B p65 (Ser276), phospho-NF-B p65 (Ser536), phospho-STAT1 (Tyr701), and phospho-STAT1 (Ser727) were the products of Cell Signaling Technology (Beverly, MA). The antibody against JAK was from Santa Cruz Biotechnology (Santa Cruz, CA). LPS, recombinant mouse IFN-␥, geldanamycin, radicicol, and anti-GAPDH antibody were all products of Sigma (St. Louis, MO). Unless otherwise indicated, all other chemicals used in this study were purchased from Sigma.
Cell culture. Mouse macrophage cells (RAW 264.7, ATCC) were grown in Dulbecco's modified Eagle's medium with 10% fetal calf serum (Invitrogen) in a 37°C humidified atmosphere of 95% air and 5% CO 2. Expression of iNOS in RAW 264.7 cells was induced by LPS (2 g/ml, serotype 026:B6) and IFN-␥ (100 U/ml) (26) .
siRNA. Small interfering RNA (siRNA) oligonucleotides targeting Hsp90 and control nonspecific siRNA were purchased from Santa Cruz Biotechnology. In six-well plates, cells were plated the day before transfection and grown to 30 -50% confluence. siRNA oligonucleotides (100 nM) were transfected into cells by using Lipofectamine 2000 reagents (Invitrogen). After 48 h of transfection, cells were subjected to further treatments and analyses.
Western blot analysis. Cells were harvested and lysed on ice for 30 min in a buffer (50 mM Tris·HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.25% sodium deoxycholate, 50 mM NaF, 1 mM Na 3VO4, 5 mM sodium pyrophosphate, and protease inhibitor tablet). Cell lysates were centrifuged at 14,000 g for 15 min, and the supernatant was recovered. Protein concentrations were determined by using the detergent-compatible protein assay kit (Bio-Rad). The proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and probed with the appropriate primary antibodies. Membrane-bound primary antibodies were detected with secondary antibodies conjugated with horseradish peroxidase. Immunoblots were developed on films using the enhanced chemiluminescence technique (SuperSignal West Pico, Pierce).
RT-PCR. Total RNA of cultured cells of cardiac tissues were extracted by using TRIzol Reagent (Invitrogen) according to the manufacturer's instructions. Reverse transcription was carried out with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). PCR was performed with Taq DNA polymerase. The following primers were used for detecting iNOS: 5=-GGGATGGCT-TGCCCCTGG-3= and 5=-CGGAGGCAGCACATCAAAG-3=. Primers 5=-GGTGAAGGTCGGAGTCAACG-3= and 5=-CAAAGTTGT-CATGGATGACC-3= were used for measuring GAPDH.
NF-B and STAT1 binding assays. The nuclei were extracted from cells by first incubating them in hypotonic buffer (10 mM Tris·HCl, pH 7.5, 10 mM NaCl, 1.5 mM MgCl 2) at 4°C for 15 min. After the cells were homogenized in a class douncer (15 strokes), cell homogenates were spun at 3,000 g for 5 min. The pellets were recovered, extensively washed, and resuspended in the nuclear extraction buffer (50 mM Tris·HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.25% sodium deoxycholate, 10% glycerol, 50 mM NaF, 1 mM Na 3VO4, and 5 mM sodium pyrophosphate, protease inhibitors). The NF-B and STAT1 binding activity of nuclear extracts were measured with the TransFactor NF-B colorimetric kit (Clontech, Mountain View) and the DuoSet mouse active STAT1 binding kit (R&D Systems, Minneapolis), respectively, according to the manufacturer's instruction.
Chromatin immunoprecipitation. RAW 264.7 cells were treated with LPS (2 g/ml) or IFN-␥ (100 U/ml) for 1 h in the presence and absence of geldanamycin. Formaldehyde (1%) was added to the culture medium, and after incubation on the rocker for 10 min at room temperature, cells were rinsed twice with 4°C ice-cold PBS and lysed for 10 min at 4°C. After sonication, 20 l of the lysate were used as DNA input control. The remaining lysate was diluted 10-fold with chromatin immunoprecipitation (ChIP) dilution buffer followed by incubation with the anti-NF-B p65 antibody (Santa-Cruz Biotechnology) or the anti-phospho-STAT1 (Tyr701) antibody (Cell Signaling Technology) overnight at 4°C. Immunoprecipitated complexes were collected using protein A/G Plus-agarose beads (Santa-Cruz Biotechnology). The precipitates were extensively washed and then incubated in the elution buffer (1% SDS and 0.1 M NaHCO 3) at room temperature for 15 min. Cross-linking of protein-DNA complexes was reversed at 65°C for 4 h. DNA was extracted with the Qiagen PCR purification kit. ChIP assays addressing NF-B used the PCR primers 5=-CAAGCCAGGGTATGTGGTTT-3= (forward) and 5=-GCAG-CAGCCATCAGGTATTT-3= (reverse), resulting in a 290-bp fragment. ChIP assays for activated STAT1 binding to its IFN-␥-regulated transcription factor STAT1␣ (GAS) site on the iNOS promoter used primers 5=-ACACGAGGCTGAGCTGACTT-3= (forward) and 5=-CACACATGGCATGGAATTTT-3= (reverse), resulting in a 186-bp fragment (24) . The resulting product was separated by 2% agarose gel electrophoresis.
Nitrite assay. Total nitrite released in cell culture medium was measured with a Griess reagent kit (Invitrogen). The reaction consisted of 20 l of Griess Reagent, 150 l of medium, and 130 l of deionized water. After incubation of the mixture for 30 min at room temperature, nitrite levels were measured at 548 nm using a M2 spectrophotometric microplate reader (Molecular Devices).
In vivo myocardial infarction in mice. C57BCL/6 mice were purchased from Charles River Laboratories. Mice were maintained in a pathogen-free environment, and experiments on mice were conducted according to the protocols approved by the University animal ethics committee. Mice were anesthetized with ketamine (55 mg/kg) plus xylazine (15 mg/kg). Animals were orally intubated with PE-90 tubing and connected to a mouse mini-ventilator (model 845; Harvard Apparatus). Core body temperature was maintained at 37°C with a thermo heating pad and monitored with the rectal thermometer. A median sternotomy was performed, and the left anterior descending coronary artery (LAD) was visualized and completely ligated for 60 min in ischemia-reperfusion mice by tightening an 8-0 silk suture after passing it over a length of PE-10 tubing beneath the LAD at points 1-2 mm inferior to the left auricle. The 8-0 suture was similarly placed in the sham group but without LAD occlusion. The PE-10 tubing was ligated with the LAD to achieve easier ligature release and better reperfusion. Ischemia was confirmed visually by the appearance of pale and bulging myocardium in the area at risk. The ligature was removed, and reperfusion was visually confirmed after 60 min of LAD occlusion. The infarcted myocardium is excised and frozen in liquid nitrogen until iNOS protein and mRNA analyses.
Statistics. Data were expressed as means Ϯ SE. Comparisons were made using a two-tailed Student's paired or unpaired t-test. Differences were considered statistically significant at P Ͻ 0.05.
RESULTS
To determine the role of Hsp90 in iNOS induction, we exposed the mouse macrophages (RAW 264.7) to LPS and IFN-␥. As shown in Fig. 1, A and B, LPS/IFN-␥ stimulated iNOS expression in a time-dependent manner. Pretreating cells with geldanamycin, a specific Hsp90 inhibitor, completely blocked iNOS expression in LPS/IFN-␥-stimulated cells. To corroborate this finding, we also examined the effect of radicicol, another specific Hsp90 inhibitor whose structure differs from that of geldanamycin (20, 27) . Similar to the action of geldanamycin, inhibiting Hsp90 with radicicol also prevented iNOS expression (Fig. 1, C and D) . To further support these findings gained with pharmacological inhibitors, we used siRNA to knock down intracellular Hsp90. As expected, Hsp90 knockdown markedly suppressed iNOS expression in LPS/ IFN-␥-stimulated cells (Fig. 1E) . Consistent with its effect on iNOS expression, NO production from LPS/IFN-␥-stimulated cells was also abolished by Hsp90 inhibition (Fig. 1F) . These data showed that Hsp90 function was essential for iNOS induction in macrophages stimulated by LPS/IFN-␥.
LPS and IFN-␥ can independently induce iNOS expression via distinctive signaling pathway. We therefore explored whether Hsp90 was required in the process of iNOS expression induced by LPS or IFN-␥ only. LPS induced a time-dependent expression of iNOS, and this was prevented by Hsp90 inhibition with either geldanamycin or radicicol (Fig. 2A) . The absence of iNOS protein could be due to the deficiency of either gene transcription or protein translation. To distinguish these possible mechanisms, we monitored iNOS mRNA for- Similar to the effects on LPS-induced iNOS expression, Hsp90 inhibition with geldanamycin or radicicol also abolished the iNOS expression in cells induced by IFN-␥ alone (Fig. 3A) . RT-PCR experiments showed that iNOS mRNA formation was prevented by Hsp90 inhibition in IFN-␥-treated cells (Fig. 3B) . Thus Hsp90 function was also indispensable in IFN-␥-stimulated iNOS gene transcription.
The above studies demonstrated that Hsp90 was necessary for iNOS induction in cultured cells exposed to inflammatory mediators. To investigate whether these cell biology findings occurred in a disease setting, we monitored iNOS expression in postischemic hearts. As shown in Fig. 4 , A and B, no iNOS protein was detected in the myocardium from the mice that received sham operations. Ischemia-reperfusion induced a significant expression of iNOS protein, and this was markedly reduced by geldanamycin. Consistent with the findings from cultured cells, decreases in iNOS protein expression in Hsp90-inhibited myocardium were also due to the reduction of iNOS mRNA transcription (Fig. 4, C and D) . These studies confirmed the essential role of Hsp90 in iNOS induction in myocardium infarction.
To explore the mechanism underlying the effect of Hsp90 inhibition on iNOS gene transactivation, we measured the effect of geldanamycin on the activation of IKK-NF-B pathway. As shown in Fig. 5 , LPS activated IKK and this resulted in subsequent degradation of IB. Interestingly, pretreatment of geldanamycin did not significantly altered LPS-initiated IKK activation and IB removal. These data suggested that Hsp90 inhibition did not block IKK-NF-B activation in LPS-treated cells. It has been reported that the full activity of NF-B p65 required the phosphorylation of its Ser536 and Ser276 residues (8). We therefore determined whether Hsp90 inhibition affected NF-B p65 phosphorylation. However, geldanamycin treatment had no significant effect on the LPS-induced alterations of NF-B p65 Ser536/276 phosphorylation in cells. We also studied the effect of geldanamycin on the JAK-STAT1 pathway in the process of iNOS expression in IFN-␥-stimulated cells. As expected, IFN-␥ activated STAT1 by triggering the phosphorylation of its Tyr701 and Ser727 residues (Fig. 6) . Geldanamycin treatment affected neither the magnitude nor the time course of STAT1 activation after IFN-␥ treatment. Short-term exposure to geldanamycin also had no significant effect on cytosolic JAK or STAT1 expression. These data demonstrated that Hsp90 inhibition did not block JAK-STAT1 activation in IFN-␥-treated cells.
To initiate gene transcription, active NF-B and STAT1 must enter nuclei (8, 12) . To determine whether Hsp90 inhibition affected nuclear transport of NF-B and STAT1, we monitored the alterations of NF-B and STAT1 levels in cytosol and nuclei from the cells stimulated in the absence and presence of geldanamycin. As shown in Fig. 7A , NF-B p65 resided in the cytosol of resting cells. LPS stimulation resulted in NF-B nuclear translocation, and this process was not altered by geldanamycin. Similarly, STAT1 was also present in the cytosol of quiescent cells. IFN-␥ triggered STAT1 transport into the nuclei. In the presence of geldanamycin, nuclear transportation of STAT1 was not significantly changed in IFN-␥-stimulated cells. Thus Hsp90 inhibition had no effect on nuclear transport of either NF-B or STAT1 in stimulated cells.
Since geldanamycin treatment did not appear to affect IKK-NF-B and JAK-STAT1 activation, we finally investigated the possibility that Hsp90 inhibition might suppress iNOS transcription by directly interfering NF-B and STAT1 binding to their DNA elements in promoters. To explore this possibility, we stimulated cells with LPS or IFN-␥ to activate NF-B or STAT1 first. Then the binding of active NF-B and STAT1 with labeled DNA oligos corresponding to their promoters was monitored in the absence and presence of geldanamycin. As shown in Fig. 8A , LPS stimulated a dramatic increase of NF-B binding activity in nuclei, and this was blocked by geldanamycin in a dose-dependent manner. A similar blocking effect of geldanamycin was also seen on STAT1-binding activity in the nuclei of IFN-␥-stimulated cells (Fig. 8B) . These data suggested that Hsp90 was required for the binding of both active NF-B and STAT1 with the DNA elements in their promoters during iNOS induction.
To prove that Hsp90 was essential for the binding of active NF-B and STAT1 to the iNOS promoter, we performed ChIP assays on iNOS promoters in stimulated cells in the absence or presence of geldanamycin (1 M). It is known that there is no NF-B and STAT1 binding to the iNOS promoter in unstimulated cells (24) . As shown in Fig. 8C , LPS-elicited NF-B binding to the iNOS promoter was largely blocked by Hsp90 inhibition. Similarly, the binding of STAT1 to the iNOS promoter was also abrogated by geldanamycin treatment in IFN-␥-stimulated cells (Fig. 8D) . Taken together, these results indicated that Hsp90 was essential for the bindings of active NF-B and STAT1 to iNOS promoters.
DISCUSSION
Hsp90 belongs to a group of highly conserved proteins known as molecular chaperon. The primary function of Hsps is to assist protein folding and maintain protein conformation. Thus Hsps play key roles in preserving normal protein structure and function (13, 20) . Although the proteins of this family can be induced to express by stress such as heat, as implicated by their names, many Hsps constitutively exist in cells. In fact, Hsp90 is one of the most abundant proteins in the cytosol (13) . The first evidence implicating Hsp90 in the regulation of NO signaling was from the studies on endothelial reactivity and vascular regulation (5). Hsp90 was found to associate with eNOS in endothelial cells, and this association appeared to be crucial for agonist-stimulated vascular relaxation. We and others subsequently showed that Hsp90 also couples with nNOS and this coupling enhances NO production (1, 20, 23) . Hsp90 augments nNOS and eNOS function apparently by promoting CaM binding to these two enzymes (22) . Intriguingly, we also found that Hsp90 interacts with iNOS, and this interaction facilitates NO synthesis despite the latter possesses an intrinsically bound CaM (27) . The significance of this protein-protein interaction is further evidenced by the studies showing that Hsp90 inhibition attenuated iNOS-induced cytotoxicity (27) . Taken together, the studies so far establish Hsp90 as an allosteric enhancer of NOS.
The key finding in the present study is that Hsp90 is required in iNOS induction. Inhibiting Hsp90 function with geldanamycin or radicicol prevented iNOS expression in cells stimulated by both LPS and IFN-␥. The results from Hsp90 knockdown experiments confirmed the essential role of Hsp90 in iNOS expression. Further studies showed that the absence of iNOS expression in Hsp90-inhibited cells was due to the lack of iNOS mRNA transcription. LPS and IFN-␥ activate the two main mechanisms by which iNOS induction is triggered. The fact that Hsp90 inhibition prevented the iNOS expression by both LPS and IFN-␥ underscored the importance of Hsp90 in iNOS induction. Indeed, in vivo animal experiments verified the necessity of Hsp90 in iNOS expression in infarcted myocardium. Thus the findings in the present study extend the role of Hsp90 from an allosteric iNOS enhancer to an obligatory contributor in iNOS induction.
Blockade of a gene transcription in stimulated cells is often due to one or multiple interruption in the signaling propagation from the stimuli to the corresponding transcriptional factors (8, 12) . However, unexpectedly we found that Hsp90 inhibition, while blocking iNOS gene transcription, had no significant effect on either IKK-NF-B or JAK-STAT1 activation in LPS/IFN-␥-stimulated cells. With HeLa cells, a cervical cancer cell line, it has been reported that Hsp90 inhibition with geldanamycin prevented TNF-induced IKK-NF-B activation (4) . However, the authors in the study (4) pretreated the HeLa cells with geldanamycin for 15 h and then examined the effect of TNF on IKK. In the present study, we found that acute Hsp90 inhibition with geldanamycin did not affect LPS-initiated IKK-NF-B activation in macrophages. Neither did we observe any significant effect on IFN-␥-stimulated JAK-STAT1 activation in cells treated by geldanamycin acutely. One the other hand, we observed that the blinding of active NF-B and STAT1 to their DNA elements was markedly blocked by Hsp90 inhibition. Further studies with ChIP assay confirmed that Hsp90 inhibition largely prevented active NF-B and STAT1 from binding to the iNOS promoter. These studies indicated that Hsp90 is directly involved in the binding of NF-B and STAT1 to the promoter in the onset of iNOS gene transcription. This may provide a plausible explanation to why iNOS gene transcription was halted despite the activation of IKK-NF-B and JAK-STAT1 was not perturbed in Hsp90-inhibited cells.
How exactly Hsp90 assists in the bindings of NF-B and STAT1 to their DNA elements in the iNOS promoter remains to be determined. As a molecular chaperon, Hsp90 is known to play a crucial role in maintaining protein conformation. For example, Hsp90 binds with hormone receptors, and this binding is important of the receptor function (20) . Hsp90 is also reported to directly associate with transcriptional factors (25) . Thus it is conceivable that the interactions between Hsp90 and NF-B or STAT1 may render the transcriptional factors a structural state favoring the binding to their respective DNA elements in iNOS promoters.
The finding on the essential role of Hsp90 in iNOS induction in postischemic hearts may provide new insight in understanding the mechanisms of ischemia preconditioning, a most effective way to protect myocardium against ischemic injury. Despite intensive research over several decades, the molecular mechanism underlying how preconditioning protects myocardium remains not fully understood (3). Nevertheless, it has long been recognized that increased levels of Hsps, including Hsp90, may be involved in the cardioprotection of ischemia preconditioning (21) . Although excessive iNOS expression has been shown to be detrimental in postischemic and failing hearts, low levels of iNOS expression may be beneficial (9) . Recently, several lines of evidence, including those from transgenic mice, suggest low levels of iNOS induction as an important mechanism that mediates the later-phase protection of ischemia preconditioning (2, 7). Whereas Hsps and iNOS are both implicated in ischemia preconditioning, these are often viewed as two separate mechanisms. The present finding that Hsp90 is required for iNOS induction suggests that the two mechanisms may be interrelated. It is possible that the protective action of increased Hsp90 in ischemia preconditioning may be conveyed via facilitating iNOS expression. On the other hand, iNOS induction in hearts undergoing preconditioning procedure is dependent on Hsp90. Future research is required to depict the details of the interaction between Hsp90 and iNOS pathway in ischemic preconditioning.
In summary, this study identified the essential role of Hsp90 in iNOS gene transactivation. Thus, besides serving as an allosteric enhancer, Hsp90 function is also required for iNOS induction. The fact that inhibiting Hsp90 prevented iNOS expression in cells and postischemic myocardium suggest that Hsp90 may be a useful target to intervene NO production in diseases such as myocardium infarction.
